SLAMF1 and neoplasm: developed a pseudoreceptor system that allows viruses retargeted to tumor‐selective CD38, EGFR or EGFR mutant vIII (EGFRvIII) to efficiently enter cells through their respective targeted receptors in vitro and in vivo, but not through CD46 and SLAM.